India & RCEP: The end of low cost medications?0

• International Trade, Op-ed
• 31/07/2017

India is the world’s largest provider of affordable medicine to developing countries. Given its ethical and economic implications, should India join a partnership agreement containing a provision as damaging as TRIPS Plus?